Document › Details
Merck KGaA. (7/30/15). "Press Release: Merck Appoints Isabel De Paoli as New Head of Group Communications". Darmstadt.
> Walter Huber will retire on March 8, 2016, following 18 years as Head of Group Communications
> Heiko Schön will take over as Head of Group Strategy on Aug. 1, 2015
Isabel De Paoli (40), currently Head of Group Strategy, has been appointed Head of Group Communications effective March 9, 2016. In her new role, she will be responsible for all global communications at Merck. Walter Huber, who currently holds the position, will retire following the Group’s annual earnings press conference on March 8, 2016. At that time, he will have just turned 60. On August 1, 2015, Isabel De Paoli will hand over operational responsibility for Group Strategy, which since the beginning of the year has also included Group Organization, to Heiko Schön (36). Isabel De Paoli will use the time until March to prepare for her new role.
“With Walter Huber an excellent communicator will be leaving. His expertise, his smart and balanced advice as well as his loyalty have been deeply appreciated inside and outside the company. Walter Huber has played an important role in helping transform the company over the past years,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck since 2007. “He’s always been open to change and able to adapt to new things without jumping on every bandwagon. His 18-year tenure is inextricably linked with the expansion and internationalization of Group Communications. We thank Walter Huber for his dedication and commitment in his almost 25-year career with Merck. I want to thank him personally for being such a good and reliable adviser even in difficult situations.”
Walter Huber had been in charge of Health Policy and Public Affairs at Merck since 1991 before taking over as Head of Group Communications in 1998. As part of his various external roles, he headed the communications committees of both, the German Chemical Industry Association (VCI) and the German Association of Research-Based Pharmaceutical Companies (VFA).
With regard to the successors in the Group Communications and Group Strategy functions Kley said: “I’m pleased that we have been able to fill those important positions with internal managers. Isabel De Paoli brings many years of experience in shaping and implementing strategic topics as well as an international background – capabilities that are becoming ever more important in a rapidly changing communications environment. Heiko Schön has driven important strategic projects with great perseverance over the past ten years and for three years now has significantly contributed to shaping the Group’s strategy.”
Merck has made it a key priority in its talent management process to fill key management positions with internal candidates. Isabel De Paoli and Heiko Schön are two examples of developing highly qualified managers at Merck over the long term.
Isabel De Paoli joined Merck in August 2006 as Business Development Manager Chemicals and was appointed Head of Strategic Planning Oncology in 2009. Since January 2012, she has been responsible for Group Strategy. Over the past three years, she has established the global function and has been responsible for leading the development of Merck’s strategy, for which she introduced a systematic strategic planning process across all businesses. Following her Chemical Engineering studies in Brazil and Hamburg, she began her career as a consultant, working for The Boston Consulting Group, from where she moved to private equity firm Permira. The future Head of Group Communications at Merck holds Brazilian and Italian citizenship and is married with two children.
Heiko Schön joined Merck in 2005 and held various positions of increasing responsibility in Group Finance before moving to Group Strategy in 2012. He has worked on important strategic projects such as the divestment of the Group’s Generics business, the integrations of both Serono and Millipore and the “Fit for 2018” transformation and growth program. The new Head of Strategy studied International Business, holds an Executive MBA and completed a Ph.D. on M&A and alliances. He is married and has a son.
Note to editors
Pictures and CVs of De Paoli and Schön can be found here.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials
Record changed: 2016-05-01
More documents for Merck (DE) (Group)
-  Merck KGaA. (3/23/17). "Press Release: FDA Grants Approval for Bavencio (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma". Darmstadt & New York, NY....
-  Merck KGaA. (3/21/17). "Press Release: Merck Introduces Mobius MyWay Portfolio for Customized Single-Use Assemblies". Darmstadt....
-  Merck KGaA. (3/21/17). "Press Release: Merck Accelerator Hits New Peak of Applications". Darmstadt....
-  Merck KGaA. (3/6/17). "Press Release: Merck Advances Lab Water Purification Technology with Milli-Q IQ 7000 System". Darmstadt....
-  Merck KGaA. (3/2/17). "Press Release: Allergopharma Opens New Biopharmaceutical Production in Reinbek". Reinbek....
-  Merck KGaA. (3/2/17). "Press Release: NICE Expands Positive Recommendation for Erbitux as First-line Treatment for RAS Wild-type mCRC". Darmstadt....
-  Merck KGaA. (2/28/17). "Press Release: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review". Darmstadt & New York, NY....
-  Merck KGaA. (2/24/17). "Press Release: Merck Receives Positive CHMP Opinion for New Pergoveris Fertility Pen". Darmstadt....
-  Merck KGaA. (2/9/17). "Press Release: Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with Multiple Sclerosis". Darmstadt....
-  Merck KGaA. (2/1/17). "Press Release: Merck Appoints Anke Schenkel as Head of Group Controlling and Risk Management". Darmstadt....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)